{"entity":{"id":"paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012","kind":"paper","name":"FIRM-ACT: combination chemotherapy in advanced adrenocortical carcinoma","aka":[],"tldr":"The first randomised trial in advanced adrenocortical carcinoma showed that etoposide, doxorubicin and cisplatin with mitotane shrank tumours more often and held them back longer than streptozocin with mitotane, making EDP-mitotane the standard.","summary":"International randomised phase 3 trial of 304 patients with advanced adrenocortical carcinoma assigned to etoposide, doxorubicin and cisplatin plus mitotane (EDP-M) or streptozocin plus mitotane, with crossover at progression.\n\nResponse rates were 23.2 percent with EDP-M against 9.2 percent, and median progression-free survival 5.0 against 2.1 months; median overall survival was 14.8 against 12.0 months, not statistically different, partly because of crossover. Serious adverse events were similar.","asOf":"2026-09-18","links":[{"label":"N Engl J Med 2012","url":"https://doi.org/10.1056/NEJMoa1200966"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/22551107/"}],"tags":[],"related":[],"cancers":["advanced-adrenocortical-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mitotane","etoposide","doxorubicin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2012,"doi":"10.1056/NEJMoa1200966","pmid":"22551107","authors":"Fassnacht M, Terzolo M, Allolio B, et al.","paperType":"rct","findings":["Response rate 23.2 percent with EDP-mitotane versus 9.2 percent with streptozocin-mitotane.","Median progression-free survival 5.0 versus 2.1 months; overall survival 14.8 versus 12.0 months (not significant)."],"whatItMeans":"EDP-mitotane is the first-line chemotherapy for adrenocortical carcinoma that cannot be removed, and the comparator arm for new trials; outcomes remain poor and better drugs are needed.","caveats":["Overall survival did not differ significantly; crossover diluted the comparison.","Toxicity of EDP-M is substantial in a population often already unwell from cortisol excess."],"changedPractice":true,"participants":304},"route":"/key-papers/paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012/","neighbours":{"cancer":[{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"mitotane","kind":"drug","name":"Mitotane","route":"/drugs/mitotane/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}